Equities analysts expect that Galapagos NV (NASDAQ:GLPG) will post $95.17 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Galapagos’ earnings, with estimates ranging from $51.92 million to $138.41 million. Galapagos reported sales of $168.33 million in the same quarter last year, which indicates a negative year-over-year growth rate of 43.5%. The company is expected to issue its next earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Galapagos will report full year sales of $601.04 million for the current year, with estimates ranging from $431.88 million to $782.07 million. For the next year, analysts forecast that the firm will report sales of $572.91 million, with estimates ranging from $212.40 million to $848.68 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Galapagos.
Galapagos (NASDAQ:GLPG) last announced its quarterly earnings results on Thursday, August 5th. The biotechnology company reported ($1.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.42) by $0.24. The company had revenue of $184.41 million during the quarter, compared to analysts’ expectations of $97.71 million. Galapagos had a negative return on equity of 8.38% and a negative net margin of 34.21%.
Shares of GLPG traded up $0.44 during trading hours on Monday, hitting $54.53. The stock had a trading volume of 5,662 shares, compared to its average volume of 290,855. Galapagos has a 1-year low of $48.66 and a 1-year high of $145.59. The firm has a market capitalization of $3.57 billion, a P/E ratio of -10.16 and a beta of 0.54. The firm has a 50 day simple moving average of $56.08 and a 200-day simple moving average of $66.99.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. The PNC Financial Services Group Inc. lifted its holdings in Galapagos by 936.4% during the 1st quarter. The PNC Financial Services Group Inc. now owns 342 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 309 shares in the last quarter. JPMorgan Chase & Co. increased its position in Galapagos by 1,217.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 448 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 414 shares during the period. Quadrant Capital Group LLC increased its position in Galapagos by 476.0% during the 2nd quarter. Quadrant Capital Group LLC now owns 576 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 476 shares during the period. Atlas Capital Advisors LLC increased its position in Galapagos by 201.1% during the 2nd quarter. Atlas Capital Advisors LLC now owns 1,048 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 700 shares during the period. Finally, Advisory Services Network LLC purchased a new position in Galapagos during the 2nd quarter valued at about $72,000. 11.27% of the stock is owned by institutional investors.
Galapagos Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
See Also: Stock Portfolio Tracker
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.